196 related articles for article (PubMed ID: 12243506)
1. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer.
Danforth DN; Aloj L; Carrasquillo JA; Bacharach SL; Chow C; Zujewski J; Whatley M; Galen B; Merino M; Neumann RD
Breast Cancer Res Treat; 2002 Sep; 75(2):135-46. PubMed ID: 12243506
[TBL] [Abstract][Full Text] [Related]
2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
5. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection.
Belhocine T; Pierard G; De Labrassinne M; Lahaye T; Rigo P
Oncologist; 2002; 7(4):271-8. PubMed ID: 12185291
[TBL] [Abstract][Full Text] [Related]
6. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of breast carcinoma and locoregional lymph nodes with positron emission tomography].
Avril N; Dose J; Ziegler S; Jänicke F; Schwaiger M
Radiologe; 1997 Sep; 37(9):741-8. PubMed ID: 9424620
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer.
Zornoza G; Garcia-Velloso MJ; Sola J; Regueira FM; Pina L; Beorlegui C
Eur J Surg Oncol; 2004 Feb; 30(1):15-9. PubMed ID: 14736517
[TBL] [Abstract][Full Text] [Related]
13. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
Rousseau C; Devillers A; Campone M; Campion L; Ferrer L; Sagan C; Ricaud M; Bridji B; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1029-36. PubMed ID: 21308372
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
15. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
16. FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients.
Borm KJ; Voppichler J; Düsberg M; Oechsner M; Vag T; Weber W; Combs SE; Duma MN
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):574-582. PubMed ID: 30118822
[TBL] [Abstract][Full Text] [Related]
17. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
18. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
20. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]